

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JAN 17 Pre-1988 INPI data added to MARPAT
NEWS 4 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist
visualization results
NEWS 5 FEB 22 The IPC thesaurus added to additional patent databases on STN
NEWS 6 FEB 22 Updates in EPFULL; IPC 8 enhancements added
NEWS 7 FEB 27 New STN AnaVist pricing effective March 1, 2006
NEWS 8 MAR 03 Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 9 MAR 22 EMBASE is now updated on a daily basis
NEWS 10 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 11 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC
thesaurus added in PCTFULL
NEWS 12 APR 04 STN AnaVist \$500 visualization usage credit offered
NEWS 13 APR 12 LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 14 APR 12 Improved structure highlighting in FQHIT and QHIT display
in MARPAT
NEWS 15 APR 12 Derwent World Patents Index to be reloaded and enhanced during
second quarter; strategies may be affected
NEWS 16 MAY 10 CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS 17 MAY 11 KOREAPAT updates resume
NEWS 18 MAY 19 Derwent World Patents Index to be reloaded and enhanced
NEWS 19 MAY 30 IPC 8 Rolled-up Core codes added to CA/CAPLUS and
USPATFULL/USPAT2
NEWS 20 MAY 30 The F-Term thesaurus is now available in CA/CAPLUS
NEWS 21 JUN 02 The first reclassification of IPC codes now complete in
INPADOC

NEWS EXPRESS JUNE 16 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 23 MAY 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available after June 2006

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:10:04 ON 19 JUN 2006

=> file pctfull
COST IN U.S. DOLLARS
FULL ESTIMATED COST

| SINCE FILE | TOTAL |
|------------|---------|
| ENTRY | SESSION |
| 0.21 | 0.21 |

FILE 'PCTFULL' ENTERED AT 16:10:19 ON 19 JUN 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED: 13 JUN 2006 <20060613/UP>
MOST RECENT UPDATE WEEK: 200623 <200623/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
SEE

<http://www.stn-international.de/stndatabases/details/ipc-reform.html> >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
(last updated April 10, 2006) <<<

=> s WO0071135/pn
L1 0 WO0071135/PN
(WO71135/PN)

=> s WO 0071135/pn
L2 0 WO 0071135/PN
(WO71135/PN)

=> s WO200071135/pn
L3 1 WO200071135/PN
(WO2000071135/PN)

=> s enhance? or synerg? or additi?
279226 ENHANCE?
36077 SYNERG?
711063 ADDITI?
L4 734288 ENHANCE? OR SYNERG? OR ADDITI?

=> s l4 and l3
L5 1 L4 AND L3

=> d ibib kwic

L5 ANSWER 1 OF 1 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2000071135 PCTFULL ED 20020515
TITLE (ENGLISH): ANTI-TUMOR COMPRISING BOROPROLINE COMPOUNDS
TITLE (FRENCH): AGENTS ANTI-TUMORALES CONTENANT DES COMPOSES DE
BOROPROLINE
INVENTOR(S): WALLNER, Barbara, P.;
MILLER, Glenn
PATENT ASSIGNEE(S): POINT THERAPEUTICS, INC.
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

| NUMBER | KIND | DATE |
|---------------|------|----------|
| WO 2000071135 | A1 | 20001130 |

DESIGNATED STATES

W:

AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ
DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS
JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN
MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR
TT TZ UA UG UZ VN YU ZA ZW GH GM KE LS MW MZ SD SL SZ

| | |
|-------------------------|---|
| | TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK |
| | ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
| | GA GN GW ML MR NE SN TD TG |
| APPLICATION INFO.: | WO 2000-US14505 A 20000525 |
| PRIORITY INFO.: | US 1999-60/135,861 19990525 |
| PI WO 2000071135 | Al 20001130 |

DETD . . . rate of division
 io and iTi. some cases uncontrolled growth. One example o 'i a
 proliferative cell disorder is a
 tumor. In addition to posing a serious health risk in and of
 themselves, primary malignant
 tumors are particularly problematic given their tendency to invade. .

In addition to agents of Formula 11, other agents useful in
 the invention include those
 in which the proline residue in Formula 11. . .

In addition, agents can be selected that are effective as
 anti-proliferative agents or as
 anti-angiogenic agents but are relatively ineffective as hemopoietic
 cell stimulatory. . .

In addition, agents of Formula I can be selected that are
 effective as anti-proliferative
 agents but are relatively ineffective as hemopoietic cell stimulatory.
 . . .

1,3-butane diol. Among the
 acceptable vehicles and solvents that may be employed are water,
 Ringer's solution, and
 isotonic sodium chloride solution. In addition, sterile, fixed
 oils are conventionally employed
 as a solvent or suspending medium. For this purpose, any bland fixed oil
 may be employed
 including synthetic mono- or di-glycerides. In addition, fatty
 acids such as oleic acid may be
 used in the preparation of injectables. Carrier formulations suitable
 for oral, subcutaneous,
 intravenous, intramuscular,. . .

vehicles include fluid and nutrient replenishers, electrolyte
 replenishers
 (such as those based on Ringer's dextrose), and the like. Preservatives
 and other additives
 may also be present such as, for example, antimicrobials, anti-oxidants,
 chelating compounds,
 and inert gases and the like. The pharmaceutical compositions may. . .

poly(valeric acid), and poly(lactide-cocaprolactone), and natural
 polymers such as
 alginate and other polysaccharides including dextran and cellulose,
 collagen, chemical
 derivatives thereof (substitutions, additions of chemical
 groups, for example, alkyl, alkylene,
 hydroxylations, oxidations, and other modifications routinely made by
 those skilled in the
 art), albumin and. . .

active component permeates at a
 controlled rate from a polymer such as described in U.S. Patent Nos.
 3,854,480, 5,133,974
 and 5,407,686. In addition, pump-based hardware delivery
 systems can be used, some of

which are adapted for implantation.

levels of IL-6 are secreted from bone marrow stromal cells of D+ and D- rats. Moreover, IL-6 levels for both strains were

enhanced by the addition of PT Bone marrow stromal cells were established from the long bones of 3 Fischer D+ and D- rats as described.

with the WEHI- 1 64 fibrosarcoma demonstrated that PT- I 00 could suppress the growth of an established s.c. tumor. In addition, when PT- I 00 administration was started shortly after implantation of VVEHI- 1 64 on day 2, it was found that not.

CLMEN. . . of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1 . -1 As all required additional search fees were timely paid by the applicant, this International Search Report covers all F searchable claims.

2 As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3 As only some of the required additional search fees were timely paid by the applicant, this International Search Report F covers only those claims for which fees were.

4 F1 No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest E1The additional search fees were accompanied by the applicant's protest.

F-1 No protest accompanied the payment of additional search fees.

Form PCT/ISA/21 0 1continuation of first sheet (1)) (July 1998)

INTERNATIONAL SEARCH REPORT

International Application No. PCTAis 00 /14505

FURTHER INFORMATION CONTINUED.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

3.13

3.34

STN INTERNATIONAL LOGOFF AT 16:11:39 ON 19 JUN 2006